SAN JOSE, Calif., Oct. 23, 2018 /PRNewswire/ -- Flex (NASDAQ:FLEX),
the Sketch-to-Scale® solutions provider that designs and
builds Intelligent Products for a Connected World®, today
announced a partnership with Novo Nordisk to develop digital health
solutions for diabetes patients. After rigorous evaluation, Novo
Nordisk selected the medical-grade BrightInsight™ platform from
Flex Digital Health to build and operate these solutions and
securely manage millions of its smart medical devices and the
corresponding data within a regulatory-compliant environment.
BrightInsight provides a unified IoT platform that enables
organizations to develop and host digital health devices, apps and
algorithms at scale while maintaining compliance with privacy,
security and regulatory requirements across the globe. Compared to
building a custom platform from scratch, BrightInsight's robust
functionality facilitates lower costs and accelerates time to
market.
"Traditional methods of managing diabetes have not kept pace
with a world moving at digital speed," said Kal Patel, M.D. and SVP of Digital Health at
Flex. "BrightInsight securely unlocks real-world data and
actionable insights, enabling pharma and medtech companies to
develop advanced, regulated digital health solutions that enable
automated clinical decisions and better engagement between
clinicians and people with diabetes."
By collaborating with Flex and utilizing Flex's established
platform, BrightInsight, Novo Nordisk can focus on developing
innovative medicines with the goal of improving patient
outcomes.
"Addressing the growing diabetes epidemic takes more than
best-in-class medicines alone. We need to engage with people on
their level and integrate with the solutions they are already using
to manage their diabetes," said Anders Dyhr
Toft, corporate vice president of Commercial Innovation at
Novo Nordisk. "Medical-grade digital health platforms like
BrightInsight are key to helping us improve the dialogue between
people with diabetes and their caregivers."
BrightInsight is an advanced, medical-grade managed service
platform that can capture and analyze data from connected medical
devices, combination products, apps or Software as a Medical Device
(SaMD) in a secure, regulatory-compliant environment.
BrightInsight's Device Master File has been accepted by the FDA and
Flex Digital Health is ISO 13485:2016 certified.
This announcement further builds on Flex's current
Sketch-to-Scale engagement to help design and manufacture elements
of Novo Nordisk's new connected insulin pens. The new partnership
with Novo Nordisk follows another recent milestone for Flex Digital
Health, the inauguration of the BrightInsight Clinical Board, which
was established to incorporate physician insight and workflow
experience in the development of digital health tools. In addition,
Flex Digital Health and the Boston Consulting Group recently
published a white paper titled, "The Evolving Role of the Biopharma
and Medtech CIO: How to Succeed in Today's Digital Era."
About Flex
Flex is the Sketch-to-Scale® solutions provider that designs
and builds Intelligent Products for a Connected World®. With
approximately 200,000 professionals across 30 countries, Flex
provides innovative design, engineering, manufacturing, real-time
supply chain insight and logistics services to companies of all
sizes in various industries and end-markets. For more information,
visit flex.com or follow us on Twitter @flexintl. Flex – Live
Smarter®
Investors & Analysts
Kevin Kessel
1 (408) 576-7985
kevin.kessel@flex.com
Media & Press
Paul Brunato
1 (408) 576-7534
paul.brunato@flex.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/flex-digital-health-announces-novo-nordisk-as-brightinsight-customer-300735928.html
SOURCE Flex